Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 3, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
- PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV - Clinical trial applications submitted for the first gene…
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
- Murray Abramson , MD, MPH appointed as Senior Vice President, Head of Clinical Development- - John Fry appointed as Strategic Clinical Advisor, Hepatitis - - Alan List , MD, Chief Medical Officer…
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 4, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash further reinforces Precision’s expected cash runway into the second half of…
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
- Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. --(BUSINESS WIRE)--Aug. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing…
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded…
Precision BioSciences to Participate in Upcoming August Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 31, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences to Report Second Quarter Results on August 1, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 8, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences Announces its Addition to the Russell Microcap® Index
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…